A compound formed when iodoacetic acid reacts with sulfhydryl groups in proteins. It has been used as an anti-infective nasal spray with mucolytic and expectorant action.
Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here.
A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. It is a protective response that serves to clear the trachea, bronchi, and/or lungs of irritants and secretions, or to prevent aspiration of foreign materials into the lungs.
Tests involving inhalation of allergens (nebulized or in dust form), nebulized pharmacologically active solutions (e.g., histamine, methacholine), or control solutions, followed by assessment of respiratory function. These tests are used in the diagnosis of asthma.
An alkylamide found in CAPSICUM that acts at TRPV CATION CHANNELS.

RIT 2214, a new biosynthetic penicillin produced by a mutant of Cephalosporium acremonium. (1/37)

A number of lysine-requiring auxotrophs of Cephalosporium acremonium were investigated for incorporation of side-chain precursors and for accumulation of beta-lactam compounds. One of the auxotrophs, Acremonium chrysogenum ATCC 20389, producing cephalosporin C and penicillin N only if grown in media supplemented with DL-alpha-amino-adipic acid (DL-alpha-AAA), was found to use L-S-carboxymethylcysteine (L-CMC) as a side-chain precursor for the synthesis of a new penicillin (RIT 2214). No corresponding cephalosporin was detected. The penicillin present in the culture filtrate, was concentrated by adsorption on activated carbon and successive column chromatography on Amberlite IRA-68 and Amberlite XAD-4. Final purification was achieved by cellulose column chromatography. RIT 2214 was identified as 6-(D)-[(2-amino-2-carboxy)-ethylthio]-acetamido]-penicillanic acid by spectral analysis, bioactivity spectrum, elucidation of side-chain structure and finally by semisynthesis. Its biological properties were also evaluated.  (+info)

Diurnal variation in the metabolism of S-carboxymethyl-L-cysteine in humans. (2/37)

The routes of metabolism of S-carboxymethyl-L-cysteine in humans are dependent on the time of dosing. Administration of 750 mg of S-carboxymethyl-L-cysteine (Day 1) during the day at 8:00 AM followed by a 8:00 AM to 4:00 PM urine collection revealed that S-carboxymethyl-L-cysteine S-oxide was the major urinary metabolite produced. The 4:00 PM to midnight urine collection resulted in S-(carboxymethylthio)-L-cysteine being identified as the major urinary metabolite. However, the administration of 750 mg of S-carboxymethyl-L-cysteine (day 15) during the night at midnight and analysis of the midnight to 8:00 AM urine collection found that thiodiglycolic acid was the major urinary metabolite, whereas thiodiglycolic S-oxide was identified as the major urinary metabolite in the 8:00 AM to 4:00 PM urine collection. A diurnal variation in the metabolism of S-carboxymethyl-L-cysteine was seen and, in particular, the timing of S-carboxymethyl-L-cysteine administration had a profound effect on the identity of urinary S-oxide metabolites produced. After administration at 8:00 AM the urinary S-oxides produced were S-carboxymethyl-L-cysteine S-oxide and S-methyl-L-cysteine S-oxide but at midnight the major urinary S-oxide metabolite produced was thiodiglycolic acid S-oxide.  (+info)

Effects of carbocysteine on antigen-induced increases in cough sensitivity and bronchial responsiveness in guinea pigs. (3/37)

Carbocysteine is a mucoactive drug and is being used for both acute and chronic infectious airway diseases. Although carbocysteine can repair the damage of epithelial cells caused by exposure to various agents, the effects of this agent on allergic airway diseases such as asthma and eosinophilic bronchitis with an isolated chronic cough, in both of which epithelial damage may be characteristic, is not clear. We investigated the effects of carbocysteine on antigen-induced cough hypersensitivity to inhaled capsaicin at 48 h and bronchial hyperresponsiveness to inhaled methacholine at 72 h after challenge with an aerosolized antigen in actively sensitized guinea pigs. After measuring bronchial responsiveness, we examined neutral endopeptidase (NEP) activity in the tracheal tissue. Carbocysteine (10, 30, or 100 mg/kg) was given intraperitoneally every 12 h for 3 days after antigen challenge. The number of coughs elicited by an aerosol of capsaicin (10(-4) M) was significantly (p < 0.01) decreased in carbocysteine groups (6.13 +/- 0.59 at 10 mg/kg, 4.88 +/- 0.67 at 30 mg/kg, and 4.50 +/- 0.33 at 100 mg/kg during 3 min measurement) compared with the control group (9.75 +/- 0.53). Furthermore, carbocysteine dose dependently repaired the antigen-induced decrease of NEP activity in the tracheal tissue, but it did not influence the bronchial hyperresponsiveness or bronchoalveolar lavage cell component. These findings suggest that carbocysteine promotes the repair of damaged epithelium by allergic reaction and may be useful in allergic airway diseases accompanied by isolated chronic coughing, especially eosinophilic bronchitis without asthma and tracheobronchitis with cough hypersensitivity.  (+info)

Does early detection of otitis media with effusion prevent delayed language development? (4/37)

OBJECTIVE: To consider whether earlier detection of otitis media with effusion (OME) in asymptomatic children in the first 4 years of life prevents delayed language development. METHODS: MEDLINE and other databases were searched and relevant references from articles reviewed. Critical appraisal and consensus development were in accordance with the methods of the Canadian Task Force on Preventive Health Care. RESULTS: No randomised controlled trials assessing the overall screening for OME and early intervention to prevent delay in acquiring language were identified, although one trial evaluated treatment in a screened population and found no benefit. The "analytic pathway" approach was therefore used, where evidence is evaluated for individual steps in a screening process. The evidence supporting the use of tools for early detection such as tympanometry, microtympanometry, acoustic reflectometry, and pneumatic otoscopy in the first 4 years of life is unclear. Some treatments (mucolytics, antibiotics, steroids) resulted in the short term resolution of effusions as measured by tympanometry. Ventilation tubes resolved effusions and improved hearing. Ventilation tubes in children with hearing loss associated with OME benefited children in the short term, but after 18 months there was no difference in comparison with those assigned to watchful waiting. Most prospective cohort studies that evaluated the association between OME and language development lacked adequate measurement of exposure or outcome, or suffered from attrition bias. Findings with regard to the association were inconsistent. CONCLUSIONS: There is insufficient evidence to support attempts at early detection of OME in the first 4 years of life in the asymptomatic child to prevent delayed language development.  (+info)

S-carboxymethylcysteine in the treatment of glue ear: quantitative systematic review. (5/37)

OBJECTIVE: To establish the clinical relevance of S-carboxymethylcysteine in the treatment of glue ear in children using measures approximating those saving a child from operation for grommet insertion. DATA SOURCES: Cochrane Library, MEDLINE, EMBASE, PubMed, reference lists and reviews were used for randomised controlled trials comparing S-carboxymethylcysteine with placebo. Seven trials involving 283 children and 146 ears were found. REVIEW METHODS: Studies were randomised, double-blind comparisons of S-carboxymethylcysteine (any dose and duration) with placebo in otitis media with effusion. Quality of trial reporting and validity of methods were assessed and used in sensitivity analysis. Main outcomes were relative benefit and number-needed-to-treat to prevent one grommet operation compared with placebo. RESULTS: Successful outcomes were obtained in 17% of children given placebo (range 5% to 38% in individual studies) and in 35% of children given S-carboxymethylcysteine (range 22 to 80%). For combined data (children and ears) the relative benefit was 2.0 (95%CI 1.4 to 2.8) and number-needed-to-treat 5.5 (95% confidence interval 3.8 to 9.8). Pooled data from trials of higher reporting quality (4/7) or methodological validity (3/7) tended to have lower efficacy but were not statistically different from those of lower quality or validity. CONCLUSION: S-carboxymethylcysteine is effective in the treatment of children with glue ear. For every five or six children treated with S-carboxymethylcysteine over one to three months, one will not undergo surgery for grommet insertion who would have done had they been given placebo. The confidence in this conclusion is limited because studies included relatively few children.  (+info)

Insights into the mechanisms of ifosfamide encephalopathy: drug metabolites have agonistic effects on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors and induce cellular acidification in mouse cortical neurons. (6/37)

Therapeutic value of the alkylating agent ifosfamide has been limited by major side effects including encephalopathy. Although the underlying biochemical processes of the neurotoxic side effects are still unclear, they could be attributed to metabolites rather than to ifosfamide itself. In the present study, the effects of selected ifosfamide metabolites on indices of neuronal activity have been investigated, in particular for S-carboxymethylcysteine (SCMC) and thiodiglycolic acid (TDGA). Because of structural similarities of SCMC with glutamate, the Ca(2+)(i) response of single mouse cortical neurons to SCMC and TDGA was investigated. SCMC, but not TDGA, evoked a robust increase in Ca(2+)(i) concentration that could be abolished by the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptor antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX), but only partly diminished by the N-methyl-D-aspartate receptor antagonist 10,11-dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine (MK=801). Cyclothiazide (CYZ), used to prevent AMPA/kainate receptor desensitization, potentiated the response to SCMC. Because activation of AMPA/kainate receptors is known to induce proton influx, the intracellular pH (pH(i)) response to SCMC was investigated. SCMC caused a concentration-dependent acidification that was amplified by CYZ. Since H(+)/monocarboxylate transporter (MCT) activity leads to similar cellular acidification, we tested its potential involvement in the pH(i) response. Application of the lactate transport inhibitor quercetin diminished the pH(i) response to SCMC and TDGA by 43 and 51%, respectively, indicating that these compounds may be substrates of MCTs. Taken together, this study indicates that hitherto apparently inert ifosfamide metabolites, in particular SCMC, activate AMPA/kainate receptors and induce cellular acidification. Both processes could provide the biochemical basis of the observed ifosfamide-associated encephalopathy.  (+info)

Effect of carbocysteine on cough reflex to capsaicin in asthmatic patients. (7/37)

AIMS: Cough, one of the main symptoms of bronchial asthma, is a chronic airway inflammatory disease with functionally damaged bronchial epithelium. Recently, we established an animal model with cough hypersensitivity after antigen challenge and clearly showed the protective effect of carbocysteine in this model. This study was designed to investigate the clinical effect of carbocysteine for cough sensitivity in patients with bronchial asthma. METHODS: The effects of the two orally active mucoregulatory drugs, carbocysteine and ambroxol hydrochloride, on cough response to inhaled capsaicin were examined in 14 patients with stable asthma. Capsaicin cough threshold, defined as the lowest concentration of capsaicin eliciting five or more coughs, was measured as an index of airway cough sensitivity. RESULTS: Geometric mean values of the cough threshold at run-in (baseline) and after 4 weeks' treatment of placebo, 1500 mg day-1 of carbocysteine and 45 mg day-1 of ambroxol hydrochloride were 12.8 micro M (95% confidence interval [CI] 5.5, 29.6), 11.0 micro M (95% CI 4.4, 27.5), 21.0 micro M (95% CI 8.8, 50.2) and 11.6 micro M (95% CI 5.8, 23.3), respectively. The cough threshold for carbocysteine was significantly greater than those of ambroxol hydrochloride (P = 0.047) and placebo (P = 0.047), respectively. CONCLUSIONS: These findings indicate that carbocysteine administration may be a novel therapeutic option for asthmatic patients, especially with cough variant asthma.  (+info)

Study about the inhibition of L-cysteine derivatives of nucleic acid bases in protein production. (8/37)

Isopoly (S-carboxymethyl-L-cysteine) derivatives of nucleic acids bases were prepared as antisense compounds. In past study, we investigated the properties of these compounds in vitro, and revealed that these compounds in vivo regulated the cell death presumably due to the inhibition of protein production. In this study, western and northern blots were carried out in order to reveal the mechanism of this inhibition for N-methyl-D-aspartate receptor in neuroblastoma x glioma hybrid NG108-15 cell line. In addition, we investigated the resistance of these compounds against cell extract and the metabolism. In conclusion, we proved that these compounds inhibited the protein production by antisense mechanism.  (+info)

The term cough is used to describe a wide range of symptoms that can be caused by various conditions affecting the respiratory system. Coughs can be classified as either dry or productive, depending on whether they produce mucus or not. Dry coughs are often described as hacking, barking, or non-productive, while productive coughs are those that bring up mucus or other substances from the lungs or airways.

Causes of Cough:

There are many potential causes of cough, including:

* Upper respiratory tract infections such as the common cold and influenza
* Lower respiratory tract infections such as bronchitis and pneumonia
* Allergies, including hay fever and allergic rhinitis
* Asthma and other chronic lung conditions
* Gastroesophageal reflux disease (GERD), which can cause coughing due to stomach acid flowing back up into the throat
* Environmental factors such as smoke, dust, and pollution
* Medications such as ACE inhibitors and beta blockers.

Symptoms of Cough:

In addition to the characteristic forceful expulsion of air from the lungs, coughs can be accompanied by a range of other symptoms that may include:

* Chest tightness or discomfort
* Shortness of breath or wheezing
* Fatigue and exhaustion
* Headache
* Sore throat or hoarseness
* Coughing up mucus or other substances.

Diagnosis and Treatment of Cough:

The diagnosis and treatment of cough will depend on the underlying cause. In some cases, a cough may be a symptom of a more serious condition that requires medical attention, such as pneumonia or asthma. In other cases, a cough may be caused by a minor infection or allergy that can be treated with over-the-counter medications and self-care measures.

Some common treatments for cough include:

* Cough suppressants such as dextromethorphan or pholcodine to relieve the urge to cough
* Expectorants such as guaifenesin to help loosen and clear mucus from the airways
* Antihistamines to reduce the severity of allergic reactions and help relieve a cough.
* Antibiotics if the cough is caused by a bacterial infection
* Inhalers and nebulizers to deliver medication directly to the lungs.

It is important to note that while cough can be a symptom of a serious condition, it is not always necessary to see a doctor for a cough. However, if you experience any of the following, you should seek medical attention:

* A persistent and severe cough that lasts for more than a few days or weeks
* A cough that worsens at night or with exertion
* Coughing up blood or mucus that is thick and yellow or greenish in color
* Shortness of breath or chest pain
* Fever, chills, or body aches that are severe or persistent.

It is also important to note that while over-the-counter medications can provide relief from symptoms, they may not address the underlying cause of the cough. If you have a persistent or severe cough, it is important to see a doctor to determine the cause and receive proper treatment.

Chalumeau M, Duijvestijn YC (May 2013). "Acetylcysteine and carbocysteine for acute upper and lower respiratory tract ...
... carbocysteine and N-acetylcysteine). Furthermore, erdosteine was the only mucolytic able to reduce the risk of hospitalization ...
... carbocysteine MeSH D12.125.119.307 - cystathionine MeSH D12.125.119.369 - cystine MeSH D12.125.119.450 - glutamic acid MeSH ... carbocysteine MeSH D12.125.166.230.330 - cysteinyldopa MeSH D12.125.166.230.369 - cystine MeSH D12.125.166.230.700 - ...
... carbocysteine MeSH D02.886.030.230.330 - cysteinyldopa MeSH D02.886.030.230.369 - cystine MeSH D02.886.030.230.700 - ...
... , also called carbocysteine, is a mucolytic that reduces the viscosity of sputum and so can be used to help ...
CARBOCYSTEINE LYSINE (UNII: 1D1Y95PXXA) PROPYLENE GLYCOL (UNII: 6DC9Q167V3) MENTHOL (UNII: L7T10EIP3A) SANGUISORBA MINOR ROOT ( ...
Sulphoxidation of carbocysteine, a drug structurally similar to D-penicillamine, displays a skewed distribution within a ... Sulphoxidation of carbocysteine, a drug structurally similar to D-penicillamine, displays a skewed distribution within a ...
Effect of carbocysteine on cough reflex to capsaicin in asthmatic patients.. Ishiura Y; Fujimura M; Yamamori C; Nobata K; Myou ...
Carbocysteine, L-Isomer Term UI T361116. Date09/13/1999. LexicalTag NON. ThesaurusID NLM (1999). ... Carbocysteine Preferred Term Term UI T006407. Date01/01/1999. LexicalTag NON. ThesaurusID ... Carbocysteine Preferred Concept UI. M0003348. Registry Number. 740J2QX53R. Related Numbers. 2387-59-9. Scope Note. A compound ... Carbocysteine. Tree Number(s). D02.886.030.230.310. D12.125.119.270. D12.125.166.230.310. Unique ID. D002233. RDF Unique ...
... carbocysteine, and N-acetylcysteine. Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Rogliani P, et al. Respir ...
The medicines contain carbocysteine, a drug that isnt approved in Canada or the U.S. because of risks such as nausea, diarrhea ...
Carbocysteine Entry term(s). 3-(Carboxymethylthio)alanine Carbocysteine, L Isomer Carbocysteine, L-Isomer L-Isomer ... Carbocysteine, L Isomer. Carbocysteine, L-Isomer. L-Isomer Carbocysteine. Mucodine. Mucodyne. Mukodin. Rhinathiol. S ... Carbocysteine - Preferred Concept UI. M0003348. Scope note. A compound formed when iodoacetic acid reacts with sulfhydryl ... use CARBOCYSTEINE to search CARBOXYMETHYLCYSTEINE 1975-79. History Note:. 91(80); was see under CYSTEINE 1980-90; was ...
Carbocysteine, L-Isomer Term UI T361116. Date09/13/1999. LexicalTag NON. ThesaurusID NLM (1999). ... Carbocysteine Preferred Term Term UI T006407. Date01/01/1999. LexicalTag NON. ThesaurusID ... Carbocysteine Preferred Concept UI. M0003348. Registry Number. 740J2QX53R. Related Numbers. 2387-59-9. Scope Note. A compound ... Carbocysteine. Tree Number(s). D02.886.030.230.310. D12.125.119.270. D12.125.166.230.310. Unique ID. D002233. RDF Unique ...
Unlike Carbocysteine systems you may be familiar with, Cezanne doesnt have the unpleasant smell. Cezanne contains Glycolic ... Most Carbocysteine products wash out very quickly, sometimes in just weeks, and have a strong, unpleasant smell. ... Yes, our ingredient list includes Carbocysteine but our process and technology is completely different from traditional ... Carbocysteine products. Cezanne is a next-generation treatment that delivers a much longer-lasting result of smoothness-minus ...
I also think about mucolytics such as Acetylcysteine ​​and Carbocysteine.. Wich effect on disulfide bridges in relation to each ...
DL-Carbocysteine [Wiki]. ; DL-cysteine, S-(carboxymethyl)-. ; MFCD00063941. ; S-(Carboxymethyl)cysteine(IUPAC). ; S-( ... D-carbocysteine [Wiki]. ; EINECS:256-722-3. ; S-(Carboxymethyl)-D-cysteine(IUPAC). ; ...
Acetylcysteine and carbocysteine seem to have a limited efficacy and appear to be safe in children older than two years. These ... Acetylcysteine and carbocysteine seem to have a limited efficacy and appear to be safe in children older than two years. These ... BACKGROUND: Acetylcysteine and carbocysteine are the most commonly prescribed mucolytic drugs in Brazil and many European and ... Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic ...
... carbocysteine, E0300742,Thiodril,carbocysteine, E0300744,Mucodyne,carbocysteine, E0300745,Furadan,carbofurane, E0300749,Vitavax ...
Carbocysteine (8). *Carbon Fiber (39). *Casirivimab and imdevimab drug combination (23). *Caspofungin (83) ...
Carbocysteine 14. Celiprolol 15. Chlophedianol 16. Chlordiazepoxide HCl 17. Chlorhexidine 18. Chlorpropamide 19. Clofibrate 20 ...
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience ...
DeCS 2008 - March 17, 2008 version. ...
NJQ5FL8Q43 CARBIPHENE C79932 7L93SJ2K9A CARBIPHENE HYDROCHLORIDE C81386 K0KA807799 CARBOCLORAL C65287 740J2QX53R CARBOCYSTEINE ...
April 22, Coppola keratin treatments, Coppola smoothing treatment, oxoacetamide carbocysteine,. Prepares the hair to optimize ... April 22, Coppola keratin treatments, Coppola smoothing treatment, oxoacetamide carbocysteine, Does Goldwell KerasilkвЂ"a new ... April 22, Coppola keratin treatments, Coppola smoothing treatment, oxoacetamide carbocysteine,. Global Keratin treatment: until ... April 22, Coppola keratin treatments, Coppola smoothing treatment, oxoacetamide carbocysteine,. Keratin Smoothing Treatment ...
Mucodynes active ingredient is Carbocysteine, a mucolytic that acts by liquefying the sputum to make it easier for the patient ...
As harsh chemicals such as formaldehyde or carbocysteine are not used in Nanoplastia treatment, it is safe for pregnant women ...
ANTI-INFECTIVE AGENTS CARBOCYSTEINE ANTI-INFECTIVE AGENTS CARBOFURAN ANTI-INFECTIVE AGENTS CARFECILLIN ANTI-INFECTIVE AGENTS ... LOCAL CARBOCYSTEINE ANTI-INFECTIVE AGENTS, LOCAL CETYLPYRIDINIUM ANTI-INFECTIVE AGENTS, LOCAL CHLORHEXIDINE ANTI-INFECTIVE ... RESPIRATORY SYSTEM AGENTS CARBOCYSTEINE RESPIRATORY SYSTEM AGENTS CLENBUTEROL RESPIRATORY SYSTEM AGENTS CODEINE RESPIRATORY ... ANTI-ALLERGIC AND RESPIRATORY SYSTEM AG CARBOCYSTEINE ANTI-ALLERGIC AND RESPIRATORY SYSTEM AG CETIRIZINE ANTI-ALLERGIC AND ...
... carbocysteine lysine salt, vitamin E, A and C), and pharmaconutritional support enriched with omega-3 fatty acids ( ... carbocysteine lysine salt, vitamin E, A and C), and pharmaconutritional support enriched with omega-3 fatty acids ( ...
Carbocysteine, Polyquaternium-10, Hydrolyzed Wheat Protein, Biotin, Tetrasodium EDTA, Sodium Citrate, Coumarin, Eugenol, ... Carbocysteine, Polyquaternium-10, Hydrolyzed Wheat Protein, Biotin, Sodium Citrate, Tetrasodium EDTA, Coumarin, Linalool, ...
CARBOCYSTEINE, COCHLEARIA OFFICINALIS EXTRACT, BETULA ALBA EXTRACT, PROPYLENE GLYCOL, ETHANOLAMINE, POLYSORBATE 20, HEXYL ...
Carbocysteine, Serine, Glutamic Acid, Cetrimonium Methosulfate, Disodium EDTA, Guar Hydroxypropyltrimonium Chloride, Isopropyl ...
Glyoxyloyl Carbocysteine, Glyoxyloyl Keratin Amino Acids, Hexyl Cinnamal, Imidazolinone, Orbignya Speciosa Kernel Oil, Parfum ( ...
... carbocysteine, hydrolyzed silk, diazolidinyl urea, methylparaben, propylparaben, citrus medica limonum peel oil, mentha ...
CARBOCYSTEINE, GLUTAMIC ACID, THREONINE, SERINE, TETRASODIUM EDTA, ETHYLHEXYLGLYCERIN, POTASSIUM SORBATE, SODIUM BENZOATE, ...
Carbocysteine, Glutamic Acid, Theonine, Serine, Tocopherol, Potassium Sorbate, Biotin, Polymethylsilsesquioxane, Glycerin, ...
  • April 22, Coppola keratin treatments, Coppola smoothing treatment, oxoacetamide carbocysteine, Kerasilk’s exclusive KeraTransform Technology with Keratin, Color-Caring Silk and segment specific, powerful ingredients gives your clients the beauty of hair like. (jewelryrepairfayetteville.com)
  • Sulphoxidation of carbocysteine, a drug structurally similar to D-penicillamine, displays a skewed distribution within a population. (nih.gov)
  • The medicines contain carbocysteine, a drug that isn't approved in Canada or the U.S. because of risks such as nausea, diarrhea, allergic reactions and gastrointestinal bleeding. (safemedicines.org)
  • Considering the inconsistent evidence resulting from the pivotal studies on mucolytic/antioxidant agents tested in chronic obstructive pulmonary disease (COPD), and the recent publication of Reducing Exacerbations and Symptoms by Treatment with ORal Erdosteine in COPD (RESTORE) study, we have performed a meta-analysis to compare the efficacy and safety of erdosteine 600 mg/day, carbocysteine 1500 mg/day, and N-acetylcysteine (NAC) 1200 mg/day in COPD. (bvsalud.org)
  • As harsh chemicals such as formaldehyde or carbocysteine are not used in Nanoplastia treatment, it is safe for pregnant women and children over the age of seven. (fabbon.com)